Education
About Us
Working with TipRanks
Follow Us
ProMIS Neurosciences (PMN)
NASDAQ:PMN
PMN Stock Chart & Stats
$0.36
-$0.04(-3.74%)
At close: 4:00 PM EST
$0.36
-$0.04(-3.74%)
Day’s Range― - ―
52-Week Range$0.35 - $1.59
Previous CloseN/A
Volume32.49K
Average Volume (3M)819.50K
Market Cap
$21.87M
Enterprise Value$12.32M
Total Cash (Recent Filing)$15.43M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Apr 06, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding53,811,110
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.49
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$4.00Price Target Upside1011.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company continues to advance its P1b 'PRECISE-AD' study of PMN310, its Aβ oligomer-targeting antibody, with enrollment ongoing in the third/final dose cohort, following a positive Data and Safety Monitoring Board (DSMB) safety review.
Financial HealthProMIS further strengthened its balance sheet by raising $21.6M in gross proceeds through July 2025 financing activities and launching an ~$18M ATM offering, which combined should provide funding into 2026.
Safety ProfileNo ARIA events have been reported to date in the ongoing P1b study, indicating a positive safety profile for PMN310.
Bears Say
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $0.35 and its highest was $1.59 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $21.87M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Apr 06, 2026 which is in 137 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on Nov 12, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.05.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -0.21.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 53,811,110 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went up 3.797%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
Company Description
ProMIS Neurosciences
ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes its proprietary technology platform to selectively target misfolded proteins implicated in these diseases, aiming to develop disease-modifying treatments. ProMIS Neurosciences operates primarily in the biotechnology and pharmaceutical sectors, leveraging advanced scientific research to address unmet medical needs in neurodegenerative conditions.
PMN Stock 12 Month Forecast
Average Price Target
$4.00
▲(1011.11% Upside)
Technical Analysis
Minerva Neurosciences
―
Immuron
―
Annovis Bio
―
Athira Pharma
―
Neurosense Therapeutics Ltd.
―
Ownership Overview
45.42% Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
54.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---